Insomnia

  • Jeffrey B. Weilburg
  • Alan J. Gelenberg

Abstract

Insomnia may be defined as difficulty falling or staying asleep, associated with compromised daytime functioning, that persists for more than 4 weeks. Most patients with insomnia have prolonged (e. g., greater than 30 min) sleep latency (time in bed to time asleep). They often have sleep that is shallow or fragmented by multiple arousals. However, no single disturbance of sleep physiology is found in all insomniacs. Some patients who complain of insomnia appear normal on objective measurements of sleep. Even patients whose complaints are matched by abnormal sleep physiology may have variations in objective sleep measures.1

Keywords

Sleep Apnea Chloral Hydrate Transient Global Amnesia Hypnotic Drug Rebound Insomnia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weilburg J. B.: Approach to the patient with insomnia, in Goroll A. H., May L. A., Mully A. G. (eds): Primary Care Medicine, 2nd ed. Philadelphia, JB Lippincott, 1987.Google Scholar
  2. 2.
    Coleman R. M., Roffwarg H. P., Kennedy S. J., et al: Sleep—wake disorders based on a polysomnographic diagnosis: A national cooperative study. JAMA 27(7):997–1003, 1982.CrossRefGoogle Scholar
  3. 3.
    Kramer P. D. : Insomnia: Importance of the differential diagnosis. Psychosomatics 23:129–137, 1982.PubMedGoogle Scholar
  4. 4.
    Hobson J. A.: Sleep Charting. South Norwalk, CT, Medication, Inc, 1983.Google Scholar
  5. 5.
    Tan T. L., Kales J. D., Kales A., et al: Inpatient multidimensional management of treatmentresistant insomnia. Psychosomatics 28:266–272, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    Zorick F. J., Roth T., Hartze K. M., et al: Evaluation and diagnosis of persistent insomnia. Am J Psychiat 38:769–773, 1981.Google Scholar
  7. 7.
    Reynolds C. F., Kupfer D. J., Taska L. S., et al: Sleep of healthy seniors: A revisit. Sleep 8:20–30, 1985.PubMedGoogle Scholar
  8. 8.
    Reynolds C. F., Kupfer D. J., Hoch, C. C., et al: Sleeping pills for the elderly: Are they ever justified? J Clin Psychiatry 46:9–12, 1985.PubMedGoogle Scholar
  9. 9.
    Weitzman E. D., Czeisler C. A., Coleman R. M., et al: Delayed sleep phase syndrome. Arch Gen Psychiatry 38:737–746, 1981.PubMedCrossRefGoogle Scholar
  10. 10.
    Czeisler C. A., Richardson G. S., Coleman R. M., et al: Chronotherapy: Resetting the circadian clocks of patients with delayed sleep phase insomnia. Sleep 4:1–21, 1981.PubMedGoogle Scholar
  11. 11.
    Reynolds C. F., Taska L. S., Sewitch D. E.: Persistent psychophysiologic insomnia: Preliminary research diagnostic criteria and EEG sleep data. Am J Psychiatry 141:804–805, 1984.PubMedGoogle Scholar
  12. 12.
    Hauri P.: Treating psychophysiologic insomnia with biofeedback. Arch Gen Psychiatry 38:752–758, 1981.PubMedCrossRefGoogle Scholar
  13. 13.
    Erman M. K. (ed): Sleep disorders. Psychiatr Clin North Am 10:4, 1987.Google Scholar
  14. 14.
    Soldatos C. R., Kales J. D., Scharf M. B., et al: Cigarette smoking associated with sleep difficulty. Science 207:551–553, 1980.PubMedCrossRefGoogle Scholar
  15. 15.
    Abernethy D. R., Greenblatt D. J., Shader R. I.: Benzodiazepine hypnotic metabolism: Drug interactions and clinical indications. Acta Psychiatr Scand 332(Suppl 74):32–38, 1986.CrossRefGoogle Scholar
  16. 16.
    Greenblatt D. J., Abernethy D. R., Shader R. I.: Benzodiazepine hypnotics: Kinetic and therapeutic options. Sleep 5:S18–S27, 1982.Google Scholar
  17. 17.
    Greenblatt D. J., Harmatz J. S., Engelhardt N., et al: Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Arch Gen Psychiatry 46:326–332, 1989.PubMedCrossRefGoogle Scholar
  18. 18.
    Church M. W., Johnson L. C.: Mood and performance of poor sleepers during repeated use of flurazepam. Psychopharmacology 61:309–316, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Morris H. H., III, Estes M. L.: Traveler’s amnesia: Transient global amnesia secondary to triazolam. JAMA 258:945–946, 1987.PubMedCrossRefGoogle Scholar
  20. 20.
    Spinweber C. L., Johnson L. C.: Effects of triazolam on sleep performance, memory and arousal threshold. Psychopharmacology (Berlin) 76:5–12, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Consensus conference drugs and insomnia. JAMA 251:2410–2416, 1984.Google Scholar
  22. 22.
    Dement W. C., Carskadon M. A., Mitler M. M., et al: Prolonged use of flurazepam. Behav Med 25–32, 1978.Google Scholar
  23. 23.
    Feinberg I., Fein G., Walker J. M., et al: Flurazepam effects on the sleep EEG. Arch Gen Psychiatry 6:95–102, 1979.CrossRefGoogle Scholar
  24. 24.
    Kales A., Scharf M. B., Kales J. D., et al: Rebound insomnia. JAMA 241:1692–1695, 1979.PubMedCrossRefGoogle Scholar
  25. 25.
    Kales A., Soldatos C. R., Bixler E. O.: Rebound insomnia and rebound anxiety: A review. Pharmacology 26:121–137, 1983.PubMedCrossRefGoogle Scholar
  26. 26.
    Greenblatt D. J., Harmatz J. S., Zinny M. A., et al: Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 317:722–728, 1987.PubMedCrossRefGoogle Scholar
  27. 27.
    Greenblatt D. J., Abernethy D. R., Doivoll M. J., et al: Pharmacokinetic properties of benzodiazepine hypnotics. J Clin Psychopharmacol 3:129–132, 1983.PubMedGoogle Scholar
  28. 28.
    Mitler M. M., Cascardon M. A., Phillips R. L., et al: Hypnotic efficacy of temazepam: A long-term sleep laboratory study. Br J Clin Pharmacol 8:635–689, 1979.CrossRefGoogle Scholar
  29. 29.
    Greenblatt D. J., Shader R. I., Divoll M., et al: Adverse reactions to triazolam, flurazepam, and placebo.Google Scholar
  30. 30.
    Kales A., Bixler E. O., Soldatos D. R., et al: Quazepam and temazepam: Effects of short- and intermediate-term use and withdrawal. Clin Pharm Ther 39:345–352, 1986.CrossRefGoogle Scholar
  31. 31.
    Kales A.: Quazepam: Hypnotic efficacy and side effects. PHarmacother 10:1–12, 1990.Google Scholar
  32. 32.
    Weilburg J. B., Donaldson S. R.: L-Tryptophan for sleep. Biol Ther Psychiatry 11:15–16, 1988.Google Scholar
  33. 33.
    Midazolam. Med Lett 28:73–74, 1986.Google Scholar
  34. 34.
    Eidson M., Philen R. M., Sewell C. M., et al: L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 335:645–648, 1990.PubMedCrossRefGoogle Scholar
  35. 35.
    Clauw D. J., Nashel D. J., Umhau A., et al: Tryptophan-associated eosinophilic connective-tissue disease. JAMA 263:1502–1506, 1990.PubMedCrossRefGoogle Scholar
  36. 36.
    Roehers T. A., Tietz E. I., Zoerck F. J., et al: Daytime sleepiness and antihistamines. Sleep 7:137–141, 1984.Google Scholar
  37. 37.
    Ware J. C.: Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 44:25–28, 1983.PubMedGoogle Scholar
  38. 38.
    Montgomery I., Oswald I., Morgan K., et al: Trazodone enhances sleep and subjective quality but not in objective duration. Br J Clin Pharmacol 16:139–144, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Jeffrey B. Weilburg
    • 1
    • 2
  • Alan J. Gelenberg
    • 3
  1. 1.Neuropsychiatry Section, Psychopharmacology UnitMassachusetts General HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Department of PsychiatryUniversity of Arizona Health Sciences CenterTucsonUSA

Personalised recommendations